Canine IL33 / Interleukin-33 / NF-HEV Protein (Native) (Cytokine)

Interleukin 33 Protein Datasheet

IL33 / Interleukin-33 / NF-HEV Protein Product Information

• Synonym: DVS27
• Protein Construction: A DNA sequence encoding the mature form of canine IL33 (O97863 ) (Ser 110-Ser 263) was expressed, with an initial Met at the N-terminus.
• Source: Canine
• Expression Host: E.coli

IL33 / Interleukin-33 / NF-HEV Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met
• Molecular Mass: The recombinant canine IL33 consists of 155 amino acids and has a calculated molecular mass of 17.8 kDa. In SDS-PAGE under reducing conditions, it migrates as an approximately 19KDa band.
• Formulation: Lyophilized from sterile 5mMEDTA PBS, pH7.5
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: IL33 / Interleukin-33 / NF-HEV protein

IL33 / Interleukin-33 / NF-HEV Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

IL33 / Interleukin-33 / NF-HEV Protein Description

Interleukin-33 (IL-33), also known as DVS 27 and NF-HEV, is a proinflammatory protein and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is expressed highly and rather selectively by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. IL-33 mediates its biological effects via Toll-interleukin 1 receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines. IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

References

1. Schmitz J. et al., 2005, Immunity. 23: 479-90.
2. Dinarello CA. 2005, Immunity. 23: 461-2.
3. Carriere V. et al., 2007, Proc Natl Acad Sci. 104 (1): 282-7.
4. Cayrol C.?et al., 2009, Proc Natl Acad Sci. 106 (22): 9021-6.